Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Olema Pharmaceuticals Inc (OLMA)

Olema Pharmaceuticals Inc (OLMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 556,354
  • Shares Outstanding, K 55,915
  • Annual Sales, $ 0 K
  • Annual Income, $ -96,660 K
  • 60-Month Beta 2.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.20
Trade OLMA with:

Options Overview Details

View History
  • Implied Volatility 110.41% ( +2.01%)
  • Historical Volatility 50.56%
  • IV Percentile 61%
  • IV Rank 47.48%
  • IV High 188.26% on 10/17/23
  • IV Low 40.04% on 06/08/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 21
  • Volume Avg (30-Day) 75
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 1,723
  • Open Int (30-Day) 1,952

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.53
  • Number of Estimates 5
  • High Estimate -0.49
  • Low Estimate -0.56
  • Prior Year -0.70
  • Growth Rate Est. (year over year) +24.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.35 +6.42%
on 04/19/24
11.73 -15.17%
on 04/12/24
-1.00 (-9.13%)
since 03/26/24
3-Month
9.35 +6.42%
on 04/19/24
16.77 -40.69%
on 02/13/24
-1.21 (-10.84%)
since 01/26/24
52-Week
4.26 +133.57%
on 04/27/23
17.79 -44.07%
on 11/08/23
+5.61 (+129.26%)
since 04/26/23

Most Recent Stories

More News
Stocks Fall as Bond Yields Climb on Strong US Economic News

The S&P 500 Index ($SPX ) (SPY ) this morning is down -1.06%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.51%. Stock indexes this...

$SPX : 5,099.96 (+1.02%)
SPY : 508.26 (+0.95%)
$DOWI : 38,239.66 (+0.40%)
DIA : 382.31 (+0.36%)
$IUXX : 17,718.30 (+1.65%)
QQQ : 431.00 (+1.54%)
^BTCUSD : 63,206.65 (-1.12%)
ZNM24 : 107-185s (+0.20%)
HUM : 305.90 (-1.77%)
CVS : 67.18 (-0.22%)
UNH : 495.35 (+0.30%)
CNC : 74.00 (-2.22%)
Stocks Retreat as Bond Yields Jump on Diminished Fed Rate Cut Prospects

The S&P 500 Index ($SPX ) (SPY ) this morning is down -1.02%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.47%. Stock indexes this...

$SPX : 5,099.96 (+1.02%)
SPY : 508.26 (+0.95%)
$DOWI : 38,239.66 (+0.40%)
DIA : 382.31 (+0.36%)
$IUXX : 17,718.30 (+1.65%)
QQQ : 431.00 (+1.54%)
ZNM24 : 107-185s (+0.20%)
HUM : 305.90 (-1.77%)
CVS : 67.18 (-0.22%)
UNH : 495.35 (+0.30%)
ELV : 537.26 (-0.45%)
CNC : 74.00 (-2.22%)
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer

USA News Group – More people are getting breast cancer this year. Around 300,000 women and 2,800 men will find out they have it. While 1 out of every 8 women will hear they have breast cancer sometime...

ONCY : 1.0900 (+0.93%)
ONC.TO : 1.47 (-1.34%)
PFE : 25.40 (+0.55%)
ARVN : 32.37 (+2.44%)
OLMA : 9.95 (+1.22%)
AZN : 75.17 (+0.19%)
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer

USA News Group – More people are getting breast cancer this year. Around 300,000 women and 2,800 men will find out they have it. While 1 out of every 8 women will hear they have breast cancer sometime...

AVRN : 0.0125 (-30.56%)
ONCY : 1.0900 (+0.93%)
ONC.TO : 1.47 (-1.34%)
PFE : 25.40 (+0.55%)
ARVN : 32.37 (+2.44%)
OLMA : 9.95 (+1.22%)
AZN : 75.17 (+0.19%)
Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Received Fast Track designation from U.S. FDA for OP-1250 for the treatment of ER+/HER2- metastatic breast cancerReported progress across OP-1250 clinical...

OLMA : 9.95 (+1.22%)
Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer

SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement...

OLMA : 9.95 (+1.22%)
Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference

SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage...

OLMA : 9.95 (+1.22%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage...

OLMA : 9.95 (+1.22%)
Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug

The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.

NVS : 97.44 (-1.64%)
PFE : 25.40 (+0.55%)
BEAM : 21.38 (-1.02%)
OLMA : 9.95 (+1.22%)
Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer

SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S....

OLMA : 9.95 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California....

See More

Key Turning Points

3rd Resistance Point 10.77
2nd Resistance Point 10.43
1st Resistance Point 10.19
Last Price 9.95
1st Support Level 9.61
2nd Support Level 9.27
3rd Support Level 9.03

See More

52-Week High 17.79
Fibonacci 61.8% 12.62
Fibonacci 50% 11.03
Last Price 9.95
Fibonacci 38.2% 9.43
52-Week Low 4.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar